FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test

The panel supported Galleri’s safety unanimously, while its effectiveness vote was narrower at six to four.

Rhea-AI Summary

GRAIL (GRAL) received a favorable FDA advisory panel vote on its Galleri cancer-screening test on September 23, 2026.

The panel voted 7–2, with one abstention, that Galleri’s benefits outweigh its risks for screening adults aged 50 and older for multiple cancers. It voted unanimously in support of safety and 6–4 in support of effectiveness. The votes are recommendations, not FDA approval. The agency is not bound by them and is expected to decide on Galleri’s premarket approval application in the coming months.

Galleri is intended to supplement, not replace, recommended screenings. It is designed to detect cancer-specific methylation patterns and predict where a detected cancer signal originated. In clinical studies, Galleri detected approximately four to seven times more cancers than standard care alone; most Galleri-detected cancers were found at earlier stages. GRAIL submitted its application on January 29, 2026. The FDA designated Galleri a Breakthrough Device in 2018.

Market Context

On Aug 07, the earlier PMA notice cited 25,490 PATHFINDER 2 participants and more than 70,000 NHS-Ga...

Analysis

On Aug 07, the earlier PMA notice cited 25,490 PATHFINDER 2 participants and more than 70,000 NHS-Galleri participants, grounding the evidence base behind this same application; the article noted the committee's recommendation was not binding on FDA.

Key Figures

Benefits versus risks vote: 7–2, with 1 abstention Safety vote: Unanimous Effectiveness vote: 6–4 +1 more

Benefits versus risks vote

7–2, with 1 abstention

Advisory Committee vote on whether Galleri's benefits outweigh its risks

Safety vote

Unanimous

Advisory Committee vote on Galleri's safety

Effectiveness vote

6–4

Advisory Committee vote on Galleri's effectiveness

Cancers detected versus standard of care

Approximately 4–7 times more

Company-reported clinical studies; compared with standard of care alone

Historical Context

1 past event · Latest: Aug 07

1 event

1. Aug 07

   FDA PMA review

   24h Move

   +9.6%

   Review meeting scheduled; the notice detailed PATHFINDER 2 and NHS-Galleri study participant counts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

premarket approval (pma), mced, investigational device exemption, methylation, +1 more

5 terms

premarket approval (pma) regulatory

"Premarket Approval (PMA) application of the Galleri® multi-cancer early detection test"

Premarket Approval (PMA) is the strict regulatory review process used by the U.S. authority for high-risk medical devices to prove they are safe and effective before they can be sold. For investors, a granted PMA is like receiving a key to a locked market: it can open exclusive sales opportunities, reduce near-term competition, and justify higher valuations, while also signaling that the company has cleared a costly, time-consuming hurdle.

mced medical

"multi-cancer early detection test (MCED)"

A multi-cancer early detection (MCED) test is a blood-based screening tool designed to detect signs of many different cancers from a single sample, often before symptoms appear. For investors, MCEDs matter because they represent a potential shift from disease-by-disease screening to a one-stop early-warning test, which could unlock large markets, change clinical practice, and carry regulatory, reimbursement and adoption risks similar to other breakthrough medical technologies; think of it as a smoke alarm that tries to spot many types of fires early.

investigational device exemption regulatory

"FDA-approved Investigational Device Exemption studies (IDEs)"

An investigational device exemption (IDE) is a regulatory permission that allows a medical device maker to test an unapproved device in people so the device’s safety and effectiveness can be studied. For investors, an IDE matters because it marks a formal step toward regulatory approval—like getting a temporary test-drive permit—and influences clinical cost, timelines, and the likelihood a device will reach the market and generate revenue.

methylation medical

"detect cancer-specific methylation patterns shared by many types of cancer"

Methylation is a chemical process where small tags called methyl groups attach to DNA or proteins, altering how genes are read without changing the underlying genetic code. Investors monitor methylation because patterns can serve as diagnostic markers, drug targets, or measures of treatment response in biotech and healthcare—think of them as sticky notes or light switches that change biological behavior and can affect a product’s development, approval and market value.

false-positive rate medical

"while maintaining a low false-positive rate"

The false-positive rate is the share of tests or signals that incorrectly say a condition exists when it does not, like a smoke alarm that sounds even though there’s no fire. For investors, a high false-positive rate can undermine confidence in a product or service, lead to extra costs, regulatory hurdles, and inflated usage numbers that don’t translate into real value or revenue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee (the Committee) of the U.S. Food and Drug Administration (FDA) for the approval of the Premarket Approval (PMA) application of the Galleri^® multi-cancer early detection test (MCED).

In three separate votes, the 10 voting members of the Committee considered Galleri's safety, effectiveness and overall benefit-risk profile for screening for the early detection of multiple types of cancer in adults aged 50 years and older. The Committee voted seven to two with one abstention that the benefits of Galleri outweigh its risks, unanimously in support of Galleri's safety, and six to four in support of Galleri's effectiveness.

"The Galleri test was developed to improve the effectiveness and efficiency of our national cancer screening program by adding multi-cancer early detection to recommended screening—helping find more cancers safely, when they may be easier and less costly to treat, and it still may be possible for a patient to receive treatment with curative intent," said Josh Ofman, MD, MSHS, CEO at GRAIL. "Today's vote reinforces the strength of Galleri's clinical evidence. We believe the panel's recommendations reaffirm a high evidence bar that GRAIL has set for a multi-cancer early detection test. GRAIL is committed to working with the FDA as it completes its review of Galleri, the first PMA submission for a multi-cancer early detection test."

The Galleri test is designed to detect cancer-specific methylation patterns shared by many types of cancer before symptoms appear, including cancers that do not have recommended screening today. When a cancer signal is detected, Galleri is designed to predict the cancer signal origin with high accuracy to help guide diagnostic evaluation. The test is intended to be used in addition to, and not as a replacement for, guideline-recommended screenings.

"We are heartened by the more than 200 physicians, nurses, professional societies, patients, patient advocates, and others who shared their support for Galleri through the written public docket and open comment period during the panel," said Ofman. "Their voices reflect the real-world urgency of finding more cancers, when outcomes can be improved."

Galleri is the only MCED test supported by large interventional and randomized controlled studies in intended-use populations, including FDA-approved Investigational Device Exemption studies (IDEs), namely PATHFINDER 2 in North America and the landmark NHS-Galleri trial in England. GRAIL's clinical development program is one of the largest in cancer screening with participants across multiple large-scale prospective studies. In clinical studies, Galleri has detected approximately four to seven times more cancers compared to standard of care alone, with most Galleri-detected cancers found at earlier stages, when treatment with curative intent may be possible, while maintaining a low false-positive rate and high Cancer Signal Origin prediction accuracy.

The FDA designated Galleri as a Breakthrough Device in 2018. GRAIL submitted its PMA application for Galleri to the FDA on Jan. 29, 2026.

The FDA convenes advisory committees to obtain independent expert advice. The agency is not bound by the Committee's recommendations, though it takes them into consideration when making final regulatory decisions. The FDA is expected to make a final decision on the Galleri PMA in the coming months.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology. GRAIL is headquartered in Sunnyvale, Calif. with locations in Washington, D.C., North Carolina, and the United Kingdom. 

For more information, visit grail.com.

GRAIL Forward Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," "would," or "will," the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include statements related to the potential benefits, uses and impacts of the Galleri test, extrapolation of trends in the results, comparability of the results to a real world setting, benefits of population screening with Galleri, the applicability of the clinical study results to the commercial or FDA versions of the Galleri test, the potential benefits of the Galleri test as voted on by the Committee, GRAIL's commitment to continue working with the FDA as the agency completes its review of the Galleri PMA, and the potential impact of the Committee's recommendation on the FDA's final regulatory decision on the Galleri PMA or other MCED tests, including the expected timing of the FDA's final regulatory decision on the Galleri PMA, among others. 

These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the period ended December 31, 2025 and our subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.

Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results, financial condition and success in our business strategies and operations may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-advisory-committee-votes-in-favor-of-approval-of-grails-galleri-multi-cancer-early-detection-test-302888303.html

SOURCE GRAIL, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did the FDA advisory panel vote on GRAIL’s Galleri test?

The panel voted 7–2, with one abstention, that Galleri’s benefits outweigh its risks for screening adults aged 50 and older for multiple cancers. It voted unanimously in support of safety and 6–4 in support of effectiveness.

Has the FDA approved GRAIL’s Galleri test after the advisory panel vote?

No. The panel’s votes are recommendations, and the FDA is not bound by them. The agency is expected to make a final decision on Galleri’s premarket approval application in the coming months.

Which studies are part of GRAIL’s Galleri clinical development program?

The program includes PATHFINDER 2 in North America and the NHS-Galleri trial in England. Both are identified as studies conducted under FDA-approved Investigational Device Exemptions.